1 month Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. BairdMarketBeat
Robert W. Baird began coverage on Contineum Therapeutics in a report on Tuesday. They set an “outperform” rating and a $32.00 target price on the stock.
X